Development of surrogate end-point biomarkers for chronic fatigue and myalgic encephalmyelitis/chronic fatigue syndrome ( ME/CFS)
- Conditions
- Myalgic encephalomyelitis/chronic fatigue sydnrome (ME/CFS) and healthy control
- Registration Number
- JPRN-UMIN000029076
- Lead Sponsor
- Osaka City University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 120
Not provided
1) Pregnant women, those who are likely to become pregnant, those who are breastfeeding 2) Person who has metal, pacemaker in the body by surgery etc. 3) Claudophobia 4) Persons who have a history of feeling sick during blood sampling 5) Persons who are experiencing psychiatric diseases before suffering chronic fatigue syndrome 6) Person who has fatigue performance status less than 4 7) A person who falls under the exclusionary disorder in ME/CFS clinical diagnostic criteria(2016) of the Ministry of Health, Labor and Welfare, a person who has undergone diagnosis of cerebral spinal fluid reduction 8) Until three month's earlier PET examination, persons who are unable to stop taking drug which may affect microglial activation or Chinese medicine with anti-inflammatory effects 9) Until one month prior to the implementation of PET, persons who are unable to stop medicines that may affect microglia activation or high antipyretics analgesic drugs with COX-1 selection system 10) BMI less than 15, more than 30 11) Others who judged inappropriate by the attending physician 12) For healthy subjects, those with a history of anemia, those with chronic fatigue and malaise, those with a history of surgery within six months, those with a history of psychiatric diseases, workers with working over 100 hours per month or shift worker with night shift, person with sleep disorder, person who has been reexamined by health check within 6 months, more than 2 in fatigue performance status
Study & Design
- Study Type
- Others,meta-analysis etc
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method